Mechanism of TangGanJian on nonalcoholic fatty liver disease with type 2 diabetes mellitus

References

• Black S, Kushner I, Samols D. 2004. C-reactive protein. J Biol Chem. 279:48487–48490.
   PubMed Web of Science ®Google Scholar
• Church LD, McDermott MF. 2009. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 11:81–89.
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. 1998. Steatohepatitis: a tale of two "hits"? Gastroenterology. 114:842–845.
   PubMed Web of Science ®Google Scholar
• Day CP. 2011. Non-alcoholic fatty liver disease: a massive problem. Clin Med (London, England). 11:176–178.
   PubMed Web of Science ®Google Scholar
• Del RD, Stewart AJ, Pellegrini N. 2005. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 15:316.
   PubMed Web of Science ®Google Scholar
• Evans JL, Goldfine ID, Maddux BA, Grodsky GM. 2002. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 23:599–622.
   PubMed Web of Science ®Google Scholar
• Evans JL, Goldfine ID, Maddux BA, Grodsky GM. 2003. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes. 52:1–8.
   PubMed Web of Science ®Google Scholar
• Evans JL, Maddux BA, Goldfine ID. 2005. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Sign. 7:1040–1052.
   PubMed Web of Science ®Google Scholar
• Fan JG. 2013. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 28:11–17.
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. 2004. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway. Hepatology. 40:185–194.
   PubMed Web of Science ®Google Scholar
• Feneberg A, Malfertheiner P. 2012. Epidemic trends of obesity with impact on metabolism and digestive diseases. Digest Dis (Basel, Switzerland). 30:143–147.
   PubMed Web of Science ®Google Scholar
• Gao HY, Huang J, Wang HY, Du XW, Cheng SM, Han Y, Wang LF, Li GY, Wang JH. 2013. Protective effect of Zhuyeqing liquor, a Chinese traditional health liquor, on acute alcohol-induced liver injury in mice. J Inflamm. 10:30–39.
   Google Scholar
• Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. 2014. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 103:137–149.
   PubMed Web of Science ®Google Scholar
• Hallak H, Ramadan B, Rubin R. 2001. Tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) by oxidant stress in cerebellar granule neurons: modulation by N-methyl-d-aspartate through calcineurin activity. J Neurochem. 77:63–70.
   PubMed Web of Science ®Google Scholar
• Hernández-Beltrán N, Moreno CB, Gutiérrez-Álvarez AM. 2013. Contribution of mitochondria to pain in diabetic neuropathy. Endocrinol Nutr. 60:25–32.
   PubMedGoogle Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (New York, NY). 259:87.
   Google Scholar
• Howard C, Noe A, Skerjanec A, Holzhauer B, Wernsing M, Ligueros-Saylan M, Thuren T. 2014. Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol. 13:94–16.
   PubMed Web of Science ®Google Scholar
• Hu A, Yan L. 2010a. Clinical observation for treating type 2 diabetes mellitus with fatty liver utilizing TangGanJian. Hubei J Trad Chin Med. 32:16–18.
   Google Scholar
• Hu A, Yan L. 2010b. Effects of TGJ on the liver function and pathological morphology of liver tissue of rats suffered from diabetes and fatty liver. J Integrated Trad Western Med. 2:229–232.
   Google Scholar
• Imani Fooladi AA, Mahmoodzadeh HH, Nourani MR, Khani S, Alavian SM. 2013. Probiotic as a novel treatment strategy against liver disease. Hepatitis Month. 13:e7521.
   PubMed Web of Science ®Google Scholar
• Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka TA, Matsuhisa M, Yamasaki Y. 2005. Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic beta-cell dysfunction and insulin resistance. Int J Biochem Cell Biol. 37:1595–1608.
   PubMed Web of Science ®Google Scholar
• Kelley DE, Mckolanis TM, Hegazi RA, Kuller LH, Kalhan SC. 2003. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocr Metabol. 285:E906.
   PubMed Web of Science ®Google Scholar
• Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. 2005. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circul Physiol. 288:H2031.
   PubMed Web of Science ®Google Scholar
• Li S, Brown MS, Goldstein JL. 2010. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA. 107:3441–3446.
   PubMed Web of Science ®Google Scholar
• Maraschin JDF. 2013. Classification of diabetes. New York (NY): Springer.
   Google Scholar
• Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, Balasubramanyam M. 2010. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem. 43:815–821.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim BI, Yun JW, Kim JW, Dong IP, Yong KC, Sung IK, Chang YP, Chong IS, Jeon WK, et al. 2004. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 19:694–698.
   PubMed Web of Science ®Google Scholar
• Qin H, Jin-Ke L, Fang L, Ru-Gui L, Guo-Qing Z, Gang L, Wei-Xing D, Hua-Bing T. 2015. Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats. World J Gastroenterol. 21:2058.
   PubMed Web of Science ®Google Scholar
• Reddy VP, Zhu X, Perry G, Smith MA. 2009. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimer's Dis. 16:763.
   PubMed Web of Science ®Google Scholar
• Schaffer SW, Jong CJ, Mozaffari M. 2012. Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited. Vasc Pharmacol. 57:139–149.
   PubMed Web of Science ®Google Scholar
• Selvaraju V, Joshi M, Suresh S, Sanchez JA, Maulik N, Maulik G. 2012. Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease—an overview. Toxicol Mech Methods. 22:330–335.
   PubMed Web of Science ®Google Scholar
• Shibata M, Hakuno F, Yamanaka D, Okajima H, Fukushima T, Hasegawa T, Ogata T, Toyoshima Y, Chida K, Kimura K, et al. 2010. Paraquat-induced oxidative stress represses phosphatidylinositol 3-kinase activities leading to impaired glucose uptake in 3T3-L1 adipocytes. J Biol Chem. 285:20915–20925.
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Lee J, Goldfine AB. 2008. Inflammation and insulin resistance. FEBS Lett. 582:97–105.
   PubMed Web of Science ®Google Scholar
• Souza BM, Assmann TS, Kliemann LM, Gross JL, Canani LH, Crispim D. 2011. The role of uncoupling protein 2 (UCP2) on the development of type 2 diabetes mellitus and its chronic complications. Arq Bras Endocrinol Metabol. 55:239–248.
   PubMedGoogle Scholar
• Szabo G, Petrasek J. 2015. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 12:387.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P. 2003. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 52:2882–2887.
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Karagiannis A. 2012. Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol. 10:162–172.
   PubMed Web of Science ®Google Scholar
• Wang J, Hu A, Zhang J. 2007. Clinical study for improving the insulin resistance of type 2 diabetes mellitus and fatty liver using TangGanJian. Hunan J Tradit Chin Med. 23:22–23.
   Google Scholar